152 related articles for article (PubMed ID: 21942426)
1. Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.
Lim J; Taoka B; Otte RD; Spencer K; Dinsmore CJ; Altman MD; Chan G; Rosenstein C; Sharma S; Su HP; Szewczak AA; Xu L; Yin H; Zugay-Murphy J; Marshall CG; Young JR
J Med Chem; 2011 Oct; 54(20):7334-49. PubMed ID: 21942426
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway.
Ioannidis S; Lamb ML; Wang T; Almeida L; Block MH; Davies AM; Peng B; Su M; Zhang HJ; Hoffmann E; Rivard C; Green I; Howard T; Pollard H; Read J; Alimzhanov M; Bebernitz G; Bell K; Ye M; Huszar D; Zinda M
J Med Chem; 2011 Jan; 54(1):262-76. PubMed ID: 21138246
[TBL] [Abstract][Full Text] [Related]
3. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
6. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
[TBL] [Abstract][Full Text] [Related]
7. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
Dugan BJ; Gingrich DE; Mesaros EF; Milkiewicz KL; Curry MA; Zulli AL; Dobrzanski P; Serdikoff C; Jan M; Angeles TS; Albom MS; Mason JL; Aimone LD; Meyer SL; Huang Z; Wells-Knecht KJ; Ator MA; Ruggeri BA; Dorsey BD
J Med Chem; 2012 Jun; 55(11):5243-54. PubMed ID: 22594690
[TBL] [Abstract][Full Text] [Related]
8. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
Zak M; Mendonca R; Balazs M; Barrett K; Bergeron P; Blair WS; Chang C; Deshmukh G; Devoss J; Dragovich PS; Eigenbrot C; Ghilardi N; Gibbons P; Gradl S; Hamman C; Hanan EJ; Harstad E; Hewitt PR; Hurley CA; Jin T; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Kulagowski JJ; Labadie S; Liao J; Liimatta M; Lin Z; Lupardus PJ; Maxey RJ; Murray JM; Pulk R; Rodriguez M; Savage S; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Xiao L; Xiao Y
J Med Chem; 2012 Jul; 55(13):6176-93. PubMed ID: 22698084
[TBL] [Abstract][Full Text] [Related]
12. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
13. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
14. Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo[e]pyrido[4,3-b]indoles series.
Nguyen CH; Lavelle F; Riou JF; Bissery MC; Huel C; Bisagni E
Anticancer Drug Des; 1992 Jun; 7(3):235-51. PubMed ID: 1319166
[TBL] [Abstract][Full Text] [Related]
15. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.
Zak M; Hurley CA; Ward SI; Bergeron P; Barrett K; Balazs M; Blair WS; Bull R; Chakravarty P; Chang C; Crackett P; Deshmukh G; DeVoss J; Dragovich PS; Eigenbrot C; Ellwood C; Gaines S; Ghilardi N; Gibbons P; Gradl S; Gribling P; Hamman C; Harstad E; Hewitt P; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Labadie S; Lee WP; Liao J; Liimatta M; Mendonca R; Narukulla R; Pulk R; Reeve A; Savage S; Shia S; Steffek M; Ubhayakar S; van Abbema A; Aliagas I; Avitabile-Woo B; Xiao Y; Yang J; Kulagowski JJ
J Med Chem; 2013 Jun; 56(11):4764-85. PubMed ID: 23659214
[TBL] [Abstract][Full Text] [Related]
16.
Yang T; Hu M; Chen Y; Xiang M; Tang M; Qi W; Shi M; He J; Yuan X; Zhang C; Liu K; Li J; Yang Z; Chen L
J Med Chem; 2020 Dec; 63(23):14921-14936. PubMed ID: 33256400
[TBL] [Abstract][Full Text] [Related]
17. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Stein BL; Crispino JD; Moliterno AR
Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
[TBL] [Abstract][Full Text] [Related]
20. 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
Weinberg LR; Albom MS; Angeles TS; Breslin HJ; Gingrich DE; Huang Z; Lisko JG; Mason JL; Milkiewicz KL; Thieu TV; Underiner TL; Wells GJ; Wells-Knecht KJ; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7325-30. PubMed ID: 22041060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
